Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years

Clostridium Infections Clinical Trial

Official title:
A Phase I, Single-center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK's Clostridium Difficile Investigational Vaccine Based on the F2 Antigen With or Without AS01B Adjuvant, When Administered Intramuscularly According to a 0, 1-month Schedule to Healthy Adults Aged Between 18-45 Years and Between 50-70 Years, Followed by an Additional Dose Administered in a Partial Blind Manner Within an Interval of Approximately 15 Months After Dose 2, in a Subcohort of Subjects Aged 50-70 Years

Status Completed

Clinical Trial Summary

The purpose of this study is to generate safety, reactogenicity (assessment of any expected or unexpected side effect of the vaccine) and immunogenicity (ability to induce an immune response) data for the development of a candidate Clostridium difficile (C. difficile) vaccine that would protect against primary cases of Clostridium difficile infection (CDI) and CDI recurrence. Clostridium difficile infection is a major cause of gastrointestinal illness with approximately 500,000 infections and the leading cause of gastroenteritis associated death with 29,000 deaths annually in the United States of America (USA). The emergence of extremely infectious varieties/types of C. difficile has contributed to increase the number and severity of CDI cases. In recent years, some countries (United Kingdom) have implemented hospital hygiene and other measures which resulted in significant reductions in the number of cases. The burden is, however, expected to remain significant until vaccination is available.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clostridium Infections

Clinical Trial Details

NCT number	NCT04026009
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 1
Start date	August 5, 2019
Completion date	May 10, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04179201` - Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
Completed	`NCT02563106` - A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI	Phase 2
Completed	`NCT00214461` - Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers	Phase 1
Completed	`NCT00314951` - Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	Phase 3
Completed	`NCT00328263` - Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients	Phase 3
Completed	`NCT00127803` - Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers	Phase 1
Completed	`NCT00350298` - Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease	Phase 2
Withdrawn	`NCT05077085` - Bezlotoxumab Versus FMT for Multiple Recurrent CDI	Phase 4
Recruiting	`NCT02681068` - MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation	N/A
Not yet recruiting	`NCT06277999` - C.Difficile Observational Study
Completed	`NCT00446355` - Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes	N/A
Terminated	`NCT00384527` - Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease	Phase 3
Completed	`NCT00269399` - A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	Phase 3
Completed	`NCT00468728` - PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	Phase 3